Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link

Giovanni Brandi; Kurt Straif; Daniele Mandrioli; Stefania Curti; Stefano Mattioli; Simona Tavolari

doi:10.5334/aogh.3660

Abstract

To date the true global incidence of intrahepatic cholangiocarcinoma (iCCA) and the underlying risk factors remain to be fully defined, in particular, the role of occupational and environmental factors. Currently, the putative role of asbestos exposure as a risk factor for iCCA is gaining increased attention in the international scientific community and agencies.

In this commentary we review and integrate available epidemiological and mechanistic evidences that support a potential role of asbestos exposure in iCCA etiology.

References

1Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019; 39: 19–31. DOI: 10.1111/liv.14095
Back to article
2Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 2016; 21: 594–599. DOI: 10.1634/theoncologist.2015-0446
Back to article
3Ransome E, Tong L, Espinosa J, Chou J, Somnay V, Munene G. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005–2014. J Gastrointest Oncol. 2019; 10: 339–347. DOI: 10.21037/jgo.2018.12.07
Back to article
4Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31: 217–223. DOI: 10.1200/JCO.2012.43.3755
Back to article
5IARC Monographs, Vol. 100B.
Back to article
6Kumagai S, Sobue T, Makiuchi T, et al. Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers. Occup Environ Med. 2016; 73: 545–552. DOI: 10.1136/oemed-2015-103427
Back to article
7IARC Monographs, Vol. 110.
Back to article
8Mimaki S, Totsuka Y, Suzuki Y, et al. Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. Carcinogenesis. 2016; 37: 817–826. DOI: 10.1093/carcin/bgw066
Back to article
9Selikoff IJ, Seidman H. Asbestos-associated deaths among insulation workers in the United States and Canada, 1967–1987. Ann. N. Y. Acad. Sci. 1991; 643: 1–14. DOI: 10.1111/j.1749-6632.1991.tb24439.x
Back to article
10Wu WT, Lin YJ, Li CY, et al. Cancer attributable to asbestos exposure in shipbreaking workers: A matched-cohort study. PLoS One. 2015; 10: e0133128. DOI: 10.1371/journal.pone.0133128
Back to article
11Luberto F, Ferrante D, Silvestri S, et al. Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy. Environ Health. 2019; 18: 71. DOI: 10.1186/s12940-019-0510-6
Back to article
12Brandi G, Di Girolamo S, Farioli A, et al. Asbestos: A hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control. 2013; 24: 911–918. DOI: 10.1007/s10552-013-0167-3
Back to article
13Farioli A, Straif K, Brandi G, et al. Occupational exposure to asbestos and risk of cholangiocarcinoma: A population-based case-control study in four Nordic countries. Occup Environ Med. 2018; 75: 191–198. DOI: 10.1136/oemed-2017-104603
Back to article
14Grosso F, Randi L, Croce A, et al. Asbestos fibers in the gallbladder of patients affected by benign biliary tract diseases. Eur J Gastroenterol Hepatol. 2015; 27: 860–864. DOI: 10.1097/MEG.0000000000000357
Back to article
15Grosso F, Croce A, Libener R, et al. Asbestos fiber identification in liver from cholangiocarcinoma patients living in an asbestos polluted area: A preliminary study. Tumori. 2019; 105: 404–410. DOI: 10.1177/0300891619839305
Back to article
16Auerbach O, Conston AS, Garfinkel L, Parks VR, Kaslow HD, Hammond EC. Presence of asbestos bodies in organs other than the lung. Chest. 1980; 77: 133–7. DOI: 10.1378/chest.77.2.133
Back to article
17Langer AM. Inorganic particles in human tissues and their association with neoplastic disease. Environ Health Perspect. 1974; 9: 229–33. DOI: 10.1289/ehp.749229
Back to article
18Padmore T, Stark C, Turkevich LA, Champion JA. Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages. Biochim. Biophys. Acta Gen. Subj. 2017; 1861: 58–67. DOI: 10.1016/j.bbagen.2016.09.031
Back to article
19Mäki-Nevala S, Sarhadi VK, Knuuttila A, et al. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing. Lung. 2016; 194: 125–135. DOI: 10.1007/s00408-015-9814-7
Back to article
20Nymark P, Aavikko M, Mäkilä J, et al. Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. Mol Oncol. 2013; 7: 29–40. DOI: 10.1016/j.molonc.2012.07.006
Back to article
21Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016; 48: 407–416. DOI: 10.1038/ng.3520
Back to article
22Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018; 8(12): 1548–1565. DOI: 10.1158/2159-8290.CD-18-0804
Back to article
23Brandi G, Deserti M, Astolfi A, et al. Whole-exome sequencing analysis identifies recurrent mutation rate in BAP1 gene in intrahepatic cholangiocarcinoma patients exposed to asbestos. Annals of Oncology. 2017; 28: vi47. DOI: 10.1093/annonc/mdx425.011
Back to article
24Brandi G, Deserti M, Palloni A, et al. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genet. 2020; 248–249: 57–62. DOI: 10.1016/j.cancergen.2020.10.001
Back to article
25Mosbeh A, Halfawy K, Abdel-Mageed WS, Sweed D, Rahman MHA. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma. Cancer Genet. 2018 Aug; 224–225: 21–28. DOI: 10.1016/j.cancergen.2018.03.002
Back to article
26Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: Benefits to patient and family members. J Transl Med. 2018; 16(1): 194. Published July 13, 2018. DOI: 10.1186/s12967-018-1559-7
Back to article
27Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013; 13: 153–159. DOI: 10.1038/nrc3459
Back to article
28Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018; 30: 102–109. DOI: 10.1016/j.joco.2018.02.005
Back to article
29Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global Asbestos Disaster. Int J Environ Res Public Health. May 16, 2018; 15(5): 1000. DOI: 10.3390/ijerph15051000
Back to article
30Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17: 557–588. DOI: 10.1038/s41575-020-0310-z
Back to article
31Exposure to hazardous chemicals at work and resulting health impacts: A global review International Labour Office. Geneva: ILO, 2021.
Back to article

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link

Abstract

Paradigm

My account